MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Non-intensive But Non-interruptive Treatment based on previously study RALL-2016 of Adult Ph-negative Acute Lymphoblastic Leukemia: No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remission (CR) with MRD-positive status after 2nd induction receive consolidation 1-3 with venetoclax (56 days), and B-ALL patients in complete remission (CR) with MRD-positive status after 2nd induction receive 1 consolidation with blinatumomab. A

Trial Details

NCT ID

NCT06237192

Phase

NA

Sponsor

National Research Center for Hematology, Russia

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• blinatumomab for B-ALL, venetoclax for T-ALL

Locations (sample)

• Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

• age 18-55 years old of patient,
• \- Clinical diagnosis of non-treated Ph-negative ALL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →